Research programme: osteoporosis therapy - BioconAlternative Names: NPH-002/004; NPT-002; Oral peptide - parathyroid hormone; Oral peptide - PTH
Latest Information Update: 10 Apr 2007
At a glance
- Originator Biocon
- Class Peptide hormones
- Mechanism of Action Parathyroid hormone receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Osteoporosis
Most Recent Events
- 11 May 2004 Preclinical trials in Osteoporosis in USA (unspecified route)
- 11 May 2004 NPH 002/004 is available for licensing (http://www.nobexcorp.com)